MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on March 17, 2005; DOI: 10.1124/mol.104.009555


0026-895X/05/6706-2077-2087$20.00
Mol Pharmacol 67:2077-2087, 2005

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.104.009555v1
67/6/2077    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jayanthi, L. D.
Right arrow Articles by Ramamoorthy, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jayanthi, L. D.
Right arrow Articles by Ramamoorthy, S.

Evidence for Biphasic Effects of Protein Kinase C on Serotonin Transporter Function, Endocytosis, and Phosphorylation

Lankupalle D. Jayanthi, Devadoss J. Samuvel, Randy D. Blakely, and Sammanda Ramamoorthy

Department of Physiology and Neuroscience, Medical University of South Carolina, Charleston, South Carolina (L.D.J., D.J.S., S.R.); and Department of Pharmacology and Center for Molecular Neuroscience, Vanderbilt University School of Medicine, Nashville, Tennessee (R.D.B.)

The serotonin transporter (SERT) regulates 5-hydroxytryptamine (serotonin) (5-HT) neurotransmission and is a high-affinity target for antidepressants and psychostimulants. In the present study, we investigated the mechanisms that contribute to a previously unidentified biphasic regulation of endogenous SERTs expressed in the platelets. Treatment of rat platelets with {beta}-phorbol 12-myristate 13-acetate (PMA) for 5 min or less resulted in a rapid inhibition of SERT involving changes in intrinsic activity of the transporter (increased Km and decreased Vmax). {beta}-PMA treatment for 30 min or more produced a sustained inhibition of SERT with a decrease only in the Vmax. Whereas inhibition of SERT activity was detected from 1 to 45 min after phorbol ester addition, the decrease in surface SERT required at least 30 min of phorbol ester incubation. Increased endocytosis of SERT accounted for the decrease in surface SERT at the later point. Protein kinase C (PKC)-mediated phosphorylation of SERT occurs on the plasma membrane during the initial phase of rapid transporter inhibition, and later, the phosphorylated SERT enters the intracellular pool. {beta}-PMA-induced phosphorylation of SERT occurs initially on serine residues(s) and then on threonine residue(s). The initial serine phosphorylation corresponded to the first phase of rapid inhibition mediated by changes in intrinsic activity and/or silencing of SERT. The later phosphorylation on threonine residue(s) corresponded to the later phase of sustained inhibition mediated by an enhanced endocytosis of SERT. Together, these data reveal that in platelets, SERT function is regulated by PKC in a biphasic manner involving both trafficking-dependent and independent mechanisms and that these two events occur at distinct phases of transporter phosphorylation.


Received November 20, 2004; accepted March 17, 2005

Address correspondence to: Dr. Sammanda Ramamoorthy, Department of Physiology and Neuroscience, Medical University of South Carolina, 173 Ashley Ave., BSB 403, Charleston, SC 29425. E-mail: rama{at}musc.edu




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
C.-B. Zhu, J. A. Steiner, J. L. Munn, L. C. Daws, W. A. Hewlett, and R. D. Blakely
Rapid Stimulation of Presynaptic Serotonin Transport by A3 Adenosine Receptors
J. Pharmacol. Exp. Ther., July 1, 2007; 322(1): 332 - 340.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
K. F. Foley, C. Pantano, A. Ciolino, and G. M. Mawe
IFN-{gamma} and TNF-{alpha} decrease serotonin transporter function and expression in Caco2 cells
Am J Physiol Gastrointest Liver Physiol, March 1, 2007; 292(3): G779 - G784.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. M. D. Carneiro and R. D. Blakely
Serotonin-, Protein Kinase C-, and Hic-5-associated Redistribution of the Platelet Serotonin Transporter
J. Biol. Chem., August 25, 2006; 281(34): 24769 - 24780.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
L. D. Jayanthi, B. Annamalai, D. J. Samuvel, U. Gether, and S. Ramamoorthy
Phosphorylation of the Norepinephrine Transporter at Threonine 258 and Serine 259 Is Linked to Protein Kinase C-mediated Transporter Internalization
J. Biol. Chem., August 18, 2006; 281(33): 23326 - 23340.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
W. Ni, K. Lookingland, and S. W. Watts
Arterial 5-Hydroxytryptamine Transporter Function Is Impaired in Deoxycorticosterone Acetate and N{omega}-Nitro-L-Arginine But Not Spontaneously Hypertensive Rats
Hypertension, July 1, 2006; 48(1): 134 - 140.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
H. C. Prasad, C.-B. Zhu, J. L. McCauley, D. J. Samuvel, S. Ramamoorthy, R. C. Shelton, W. A. Hewlett, J. S. Sutcliffe, and R. D. Blakely
Human serotonin transporter variants display altered sensitivity to protein kinase G and p38 mitogen-activated protein kinase
PNAS, August 9, 2005; 102(32): 11545 - 11550.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics